CLSN
Imunon, Inc.
Set alert
1.95 0.00 0.00%
1.93 Day range 1.99
52-week range unavailable
- Open
- 1.96
- Prev close
- 1.95
- Mkt cap
- 13.91M
- Vol
- 56.81K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.93
- High
- 1.99
- Forward P/E
- -0.52
- Beta
- 2.26
- Short ratio
- 0.72
- Inst. own
- 15.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 15, 2022
- 50-d avg
- 2.20
- 200-d avg
- 2.52
- 1y target
- 27.00
Key statistics
- Market cap
- 13.91M
- Enterprise value
- -21.74M
- Trailing P/E
- 0.00
- Forward P/E
- -0.52
- PEG ratio
- 0.00
- Price / sales
- 27.83
- Price / book
- 0.30
- EPS (TTM)
- -3.97
- Beta
- 2.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 500.00K
- Revenue growth
- 0.00%
- Free cash flow
- -12.92M
- Total cash
- 42.11M
- Total debt
- 6.46M
- Return on equity
- -47.08%
- Shares outstanding
- 7.10M
- Short % of float
- 0.79%
- 50-day average
- 2.20
- 200-day average
- 2.52
Analyst view
Consensus: buy
Buy
Price target (mean) 27.00 +1287.0% upside
Now 1.95
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 45.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 15, 2022
Expected Aug 15, 2022. Consensus EPS estimate -0.81.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2022 | Jun 1, 2022 | -1.12 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -1.01 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | -0.90 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | -1.20 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -1.20 | — | — | — |
| May 14, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 13, 2022 | HC Wainwright & Co. | init | — | Buy |
| Nov 22, 2017 | Oppenheimer | init | — | Outperform |
| Oct 5, 2017 | Maxim Group | up | Hold | Buy |
| Jul 15, 2015 | Maxim Group | init | — | Buy |
| Jul 13, 2015 | BTIG Research | init | — | Buy |
| Sep 30, 2013 | H.C. Wainwright | init | — | Buy |
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celsion.com
News
- Celsion Corporation Announces Company Name Change to Imunon, Inc.
- Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
- Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
- Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
- Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
- Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
- Earnings Scheduled For August 15, 2022
- Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
- Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Your note
Sign in to keep a note on CLSN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORYS NICHOLAS | Officer | Stock Award(Grant) | Feb 1, 2016 | 19,926 |
| BRAUN DONALD P | Director | Purchase | May 16, 2021 | 5,357 |
| CHURCH JEFFREY WAYNE | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2020 | 54,298 |
| FRITZ FREDERICK J | Director | Purchase | Apr 7, 2022 | 11,766 |
| HOOPER ROBERT W | Director | Purchase | Oct 2, 2018 | 25,687 |
| KARDARAS CONSTANTINE JOHN | Officer | Stock Award(Grant) | Dec 13, 2021 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Murchinson Ltd. | 3.90% | 276,644 | 542.22K | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 3.31% | 234,953 | 460.51K | Jun 29, 2022 |
| Two Sigma Advisers, LP | 1.61% | 114,304 | 224.03K | Jun 29, 2022 |
| Blackrock Inc. | 0.95% | 67,730 | 132.75K | Jun 29, 2022 |
| Susquehanna International Group, LLP | 0.74% | 52,274 | 102.46K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 0.74% | 52,311 | 102.53K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.94% | 137,780 | 270.05K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.12% | 79,599 | 156.01K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.42% | 29,987 | 58.77K | Jun 29, 2022 |
| iShares Micro Cap ETF | 0.18% | 12,780 | 25.05K | May 30, 2022 |
| Vanguard Balanced Index Fund | 0.13% | 9,191 | 18.01K | Jun 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.12% | 8,671 | 17.00K | Aug 30, 2022 |